Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine Reduces Exacerbation Rate and Risk in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

By sjmartinez • September 1, 2024

Sciurba FC, Christenson SA, Rheault T, Bengtsson T, Rickard K, Barjaktarevic IZ. Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine Reduces Exacerbation Rate and Risk in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Chest. 2024 Aug 26:S0012-3692(24)04937-7. doi: 10.1016/j.chest.2024.07.168. Epub ahead of print. PMID: 39197510.

Tags: chronic obstructive pulmonary disorder, ensifentrine, exacerbation, patient-reported outcomes, Publications, Pulmonary, Critical Care & Sleep Medicine

Related Posts

Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system ImPrEP CAB Brasil: a hybrid type-2 implementation-effectiveness cohort study

Grinsztejn B, Torres TS, Hoagland B, Coutinho C, Silva MST, Leite IC, Cunha M, Derrico M, Jalil EM, Cardoso SW, Trefiglio R, Farias A, Mourão[...]

Getting to best practice: a practice-oriented checklist for monitoring clinic-level fidelity to hypertension interventions in a large safety-net healthcare system

Korn AR, Gandhi P, R Dopp A, Barron J, Casillas-Salazar R, Durant C, G Morales M, Norwood-Scott E, L Carson S, Casillas A, B Hamilton[...]

Air Pollution Triggers Metabolomic Signature of Mitochondrial Dysfunction in Mice and Humans: Implications for Cardiovascular Disease Development

Lin Y, Qiu X, Gupta R, Ramanathan G, Lu X, Yin F, Fiehn O, Zhang JJ, Kaufman JD, Zhu Y, Rosenfeld M, Araujo JA. Air[...]